DSP-2230
From Wikipedia, the free encyclopedia
Jump to: navigation, search
DSP-2230 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
See also[edit]
References[edit]
- ^ a b Martz, Lauren (2014). "Nav-i-gating antibodies for pain". Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662. ISSN 1945-3477.
- ^ a b Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.
| Opioids | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paracetamol-type | |||||||||||||||||||||||||||||||
| NSAIDs |
|
||||||||||||||||||||||||||||||
| Cannabinoids | |||||||||||||||||||||||||||||||
| Ion channel modulators |
|
||||||||||||||||||||||||||||||
| Myorelaxants | |||||||||||||||||||||||||||||||
| Others | |||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=DSP-2230&oldid=712094319"
